SCHEMBL6340227

SCHEMBL6340227

C=C(C(=O)OCC)c1ccccc1Oc1ccc(Cl)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.52
ALDH1A1 P00352 3/20 0.47
GAA P10253 3/20 0.47
ATM Q13315 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
HPGD P15428 1/20 0.47
HTT P42858 1/20 0.47
TSHR P16473 3/20 0.46
PNLIP P16233 3/20 0.46
CYP1A2 P05177 3/20 0.43
POLB P06746 1/20 0.43
BRD4 O60885 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
HTR2A P28223 3/20 0.42
SLC6A4 P31645 2/20 0.42
PPARA Q07869 2/20 0.42
SLC6A2 P23975 1/20 0.42
SLC6A3 Q01959 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6335524 0.89 TSHR (0.48) MAPTALDH1A1L3MBTL1HPGDTSHR
SCHEMBL22589051 0.89 TSHR (0.56) MAPTALDH1A1L3MBTL1HPGDTSHR
SCHEMBL6340117 0.88 KMT2A (0.50) MAPTALDH1A1GAAATML3MBTL1
SCHEMBL6337567 0.88 TSHR (0.47) MAPTALDH1A1GAAL3MBTL1TSHR
SCHEMBL6333862 0.87 TSHR (0.46) MAPTALDH1A1L3MBTL1HPGDTSHR
SCHEMBL28813465 0.85 MAPT (0.52) MAPTALDH1A1GAAATML3MBTL1
SCHEMBL4779721 0.79 MAPT (0.57) MAPTALDH1A1GAAL3MBTL1HPGD
SCHEMBL30364396 0.79 MAPT (0.57) MAPTALDH1A1GAAL3MBTL1HPGD
SCHEMBL16672822 0.79 HCRTR1 (0.54) MAPTALDH1A1GAAL3MBTL1HPGD
SCHEMBL27894324 0.77 MAPT (0.68) MAPTALDH1A1GAAATML3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6967197-B2 Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-11-22 US disclosed
US-20030134849-A1 Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-07-17 US disclosed
WO-2003018019-A2 NEW USE OF CYCLIC COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-03-06 WO disclosed
EP-1259499-A1 THIAZEPINYL HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-11-27 EP disclosed
WO-2001060808-A1 THIAZEPINYL HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030134849-A1 Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors MMP9, MMP1, MMP3 MAPT 4811/4885ALDH1A1 543/4885GAA 946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.